- Home
- INVE vs CALC Comparison
INVE vs CALC Comparison
Compare INVE & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | CALC |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 88.3M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVE | CALC |
|---|---|---|
| Price | $3.41 | $0.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.50 | ★ $10.00 |
| AVG Volume (30 Days) | 32.5K | ★ 505.0K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1182.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.86 | $0.46 |
| 52 Week High | $4.07 | $7.20 |
Technical Indicators
Market Signals| Indicator | INVE | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 29.99 |
| Support Level | $3.40 | $0.49 |
| Resistance Level | $3.49 | $0.79 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 56.49 | 67.69 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.